Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes

Endocrine Journal

Volumn 58, Issue 4, 2011, Pages 315-322

  Saisho, Yoshifumi ^a   Kou, Kinsei ^a   Tanaka, Kumiko ^a   Abe, Takayuki ^a   Kurosawa, Hideaki ^a   Shimada, Akira ^b   Meguro, Shu ^a   Kawai, Toshihide ^a   Itoh, Hiroshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

Author keywords

Beta cell function; C peptide; Insulin; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOREACTIVITY; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

AGED; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 79955781269     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-399     Document Type: Article

References (17)

1. Defronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773-795.
2. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC (1998) UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15: 297-303.
3. Festa A, Williams K, D'Agostino R, Jr., Wagenknecht LE, Haffner SM (2006) The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55: 1114-1120.
4. Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, Ikeda K, Hamamoto Y, Hosokawa M, Seino Y, Inagaki N (2008) Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract 82: 353-358.
5. Tsai EB, Sherry NA, Palmer JP, Herold KC (2006) The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 49: 261-270.
6. Torn C (2003) C-peptide and autoimmune markers in diabetes. Clin Lab 49: 1-10.
7. Asano T, Kawamura M, Watanabe T, Abe M, Chin R, Miyazaki S, Hirata Y (2008) Indices of urinary and serum c-peptide corrected with fasting plasma glucose for decision-making of insulin therapy in type 2 diabetes-validation and comparison. J Japan Diab Soc 51: 759-763 (In Japanese).
8. Goto A, Takaichi M, Kishimoto M, Takahashi Y, Kajio H, Shimbo T, Noda M (2010) Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr J 57: 237-244.
9. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H (2008) Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 371: 1753-1760.
10. Alvarsson M, Sundkvist G, Lager I, Berntorp K, Fernqvist-Forbes E, Steen L, Orn T, Holberg MA, Kirksaether N, Grill V (2008) Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab 10: 421-429.
11. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD (2008) Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 31: 1927-1932.
12. The Japan Diabetes Society (2004) Evidence-based practice guideline for the treatment of diabetes in Japan. Nankodo, Tokyo (In Japanese).
13. Saisho Y, Miyakoshi K, Tanaka M, Shimada A, Ikenoue S, Kadohira I, Yoshimura Y, Itoh H (2010) Beta cell dysfunction and its clinical significance in gestational diabetes. Endocr J 57: 973-980.
14. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa M, Haneda M, Ueki K (2010) Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Japan Diab Soc 53: 450-467 (In Japanese).
15. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992.
16. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S (2010) Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis 56: 32-38.
17. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.